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ABSTRACT
Objective: To establish and evaluate the effectiveness of a comprehensive next-generation
sequencing (NGS) approach to simultaneously analyze all genes known to be responsible for
the most clinically and genetically heterogeneous neuromuscular diseases (NMDs) involving spi-
nal motoneurons, neuromuscular junctions, nerves, and muscles.
Methods: All coding exons and at least 20 bp of flanking intronic sequences of 236 genes causing
NMDs were enriched by using SeqCap EZ solution-based capture and enrichment method fol-
lowed by massively parallel sequencing on Illumina HiSeq2000.
Results: The target gene capture/deep sequencing provides an average coverage of;1,0003 per
nucleotide. Thirty-five unrelated NMD families (38 patients) with clinical and/or muscle pathologic
diagnoses but without identified causative genetic defects were analyzed. Deleterious mutations
were found in 29 families (83%). Definitive causative mutations were identified in 21 families
(60%) and likely diagnoses were established in 8 families (23%). Six families were left without
diagnosis due to uncertainty in phenotype/genotype correlation and/or unidentified causative
genes. Using this comprehensive panel, we not only identified mutations in expected genes but
also expanded phenotype/genotype among different subcategories of NMDs.
Conclusions: Target gene capture/deep sequencing approach can greatly improve the genetic
diagnosis of NMDs. This study demonstrated the power of NGS in confirming and expanding clin-
ical phenotypes/genotypes of the extremely heterogeneous NMDs. Confirmed molecular diagno-
ses of NMDs can assist in genetic counseling and carrier detection as well as guide therapeutic
options for treatable disorders. Neurol Genet 2015;1:e14; doi: 10.1212/NXG.0000000000000015
GLOSSARY
AD 5 autosomal dominant; AR 5 autosomal recessive; BCM 5 Baylor College of Medicine; CACTD 5 carnitine acylcarnitine
translocase deficiency; CCD 5 central core disease; CM 5 congenital myopathy; CMD 5 congenital muscular dystrophy;
CMT 5 Charcot-Marie-Tooth disease; CMyS 5 congenital myasthenic syndrome; CNM 5 centronuclear myopathy; EDMD 5
Emery-Dreifuss muscular dystrophy; HSAN 5 hereditary sensory and autonomic neuropathy; LGMD 5 limb-girdle muscular
dystrophy; MH 5 malignant hyperthermia; MM 5 metabolic myopathy; MTS 5 myotonic syndrome; NGS 5 next-generation
sequencing;NM5 nemaline myopathy;NMD5 neuromuscular disease; PFIS5 paralytic floppy infant syndrome; SMARD15
spinal muscular atrophy with respiratory distress type 1; VUS 5 variants of unknown significance.
Neuromuscular diseases (NMDs) are genetically and clinically heterogeneous. To date, more
than 360 genes have been reported to cause NMDs.1 As a group, the combined NMD prev-
alence is greater than 1 in 3,000.2
The majority of NMDs are inherited, degenerative, and rare.3,4 An early definitive molecular
diagnosis is crucial for genetic counseling, family planning, prognosis, therapeutic strategies, and
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long-term care plans.3–7 The recent develop-
ment of next-generation sequencing (NGS)
has accelerated the discovery of novel NMD
phenotypes and genotypes,8–11 including the
identification of mutations in 5 large NMD
genes (TTN, NEB, SYNE1, RYR1, and
DMD1,4,8–12) (table e-1 at Neurology.org/ng).
With the ever-increasing number of causative
genes and clinical heterogeneity, a comprehen-
sive molecular approach with the feasibility
to add newly discovered genes for analysis
in a cost- and time-effective manner is
needed.1,4,7,12–16
A recent study using PCR enrichment and
NGS approach to analyze 12 genes known
to cause congenital muscular dystrophy
(CMD) on 26 samples with known muta-
tions17 reported that 49 exons (15%) had
insufficient coverage (,203).17 Among 15
known variants, 6 (40%) were not detected.
Similar studies on congenital myasthenic
syndrome (CMyS),18 Charcot-Marie-Tooth
disease (CMT),19 Duchenne/Becker muscular
dystrophy,20 and metabolic myopathy (MM)21,22
have demonstrated the clinical utility of NGS in
specific disease categories. Nevertheless, these are
small-scale studies focusing on subcategories of
NMDs. Here, we describe a comprehensive
target gene capture/NGS approach, analyzing
236 genes.
METHODS Standard protocol approvals, registrations,
and patient consents. This study was conducted according to
the Institutional Review Board–approved protocols of both
Kaohsiung Medical University Hospital, Taiwan, and Baylor
College of Medicine (BCM), Houston, TX. A signed informed
consent was obtained for each participant.
Patients and DNA samples. Patients were clinically evaluated
in Taiwan, and DNA samples were analyzed at BCM. DNA sam-
ples from 35 unrelated families (38 patients) with clinical diagnoses
of NMD who underwent electrophysiologic examination and
muscle imaging and/or muscle biopsies were analyzed. Patients
with a proven common genetic diagnosis of spinal muscular atro-
phy, Duchenne muscular dystrophy, myotonic dystrophy types
1 and 2, CMT type 1A, or facioscapulohumeral muscular dystro-
phy were not included in the study. The initial diagnoses included
congenital myopathy (CM) (23 patients), CMD (5), limb-girdle
muscular dystrophy (LGMD)23 (4), CMT (3), MM (2), and
myotonic syndrome (MTS) and ion channel muscle disease (1).
DNA was extracted from peripheral blood using a Puregene DNA
extraction kit according to manufacturer’s instructions (Gentra
Systems Inc., Minneapolis, MN).
Design of capture probes and target gene enrichment. The
capture probe library contained 236 genes, most of which were
selected from the 2012 version of the gene table of monogenic
NMDs.24 We categorized NMDs and their causative genes into
10 groups, including MM, CMD, CM, other myopathies, motor
neuron disease, CMyS, arthrogryposis multiplex congenita, MTS
and ion channel muscle diseases, CMT, and other muscular dystro-
phies as listed in table 1. Mitochondrial genes were not included.
A custom NimbleGen in-solution DNA capture library was
designed to capture all 4,815 coding exons and at least 20 bp
flanking intron regions of the 236 NMD-related genes. The
NM accession numbers of the genes are listed in table e-1. The
coding regions were enriched according to manufacturer’s in-
structions (Roche NimbleGen Inc., Madison, WI) and sequenc-
ing was performed on HiSeq2000, as previously described.21,25
Sequence alignment and analytical pipeline for variant
calling. Conversion of raw sequencing data, demultiplexing,
sequence alignment, data filtering, and analyses using CASAVA
v1.7, NextGENe software were performed as previously
described.21,25 Multiple in silico analytical tools, such as
SpliceSiteFinder-like, MaxEntScan, NNSPLICE, and GeneSplicer,
were used to predict the effects of splice site variants (Alamut, http://
www.interactive-biosoftware.com). SIFT26 and PolyPhen-227 were
used to predict the pathogenicity of novel missense variants. The
pathogenicity of the variants was categorized according to published
databases, such as Human Gene Mutation Database (http://www.
biobase-international.com/product/hgmd), PubMed (http://www.
ncbi.nlm.nih.gov/pubmed), and American College of Medical
Genetics guidelines.28 The analytical flowchart is depicted in
figure e-1. All mutations and novel variants identified by NGS
were confirmed independently by Sanger sequencing.21,25 Family
members, if available, were also tested to evaluate the mode of
inheritance, disease segregation, and clinical correlation.
Detection of deletions using sequence read coverage data
from NGS. We used a newly developed analytical method to
detect exonic deletions using the same set of NGS data by com-
paring the normalized coverage depth of each individual exon of
the test sample with the mean coverage depth of the same exon
from a group of 20 reference samples.29
RESULTS Characteristics of target gene capture and
sequence depth. More than 99.4% (4,787/4,815) of
the target sequences were enriched in an unbiased
fashion, with a minimal coverage of 203 and a mean
coverage depth of 1,1363 per base (figure 1). An
average of 28 exons per sample was consistently insuf-
ficiently sequenced (,203) due to the high GC
content, sequence homologies in the genome, short
tandem repeats, or secondary structural difficulties
(table e-2).
Clinical history. A total of 35 unrelated affected fami-
lies (38 patients) with clinical diagnosis of NMDwere
studied. Among them, 3 families had 2 affected fam-
ily members (patients 4/6, 19/20, and 25/26). The
male to female patient ratio was about 1 to 1. The
majority of patients (27/38, 71%) presented with par-
alytic floppy infant syndrome (PFIS). The clinical and
pathologic features are summarized in table 2.
Identification of mutations. Figure e-1 illustrates the
analytical algorithm for the identification of disease-
causing variants. The approximate number of
variants in each step of analysis is included. DNA
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sequence variants were considered deleterious if they
led to a translational frameshift, exon skipping, or
stop codon or if they were previously reported in
affected patients. Table 2 summarizes initial clinical
diagnoses, muscle pathology findings, mutations
identified, and final diagnoses. Among 35 families,
21 families (60%) had definitive diagnoses with
deleterious mutations in the expected causative
genes that were confirmed in family members.
Likely diagnoses were identified in an additional 8
families (23%) that had novel genotype/phenotype
findings requiring functional, clinical, and/or
genetic confirmation. Six families were without a
specific diagnosis due to inconsistent genotype/
phenotype correlation based on current knowledge.
Similar to the proportion of clinical diagnoses,
mutations in genes causing CM were most
common. However, this observation is biased due
to the prevalence of pediatric patients in our cohort.
About half of the disorders are inherited in an
autosomal recessive (AR) mode, with 2 X-linked
recessive cases. Autosomal dominant (AD) disorders
account for about 20%.
Molecular diagnoses of NMDs. Confirmation of NMD
diagnosis: Identification of deleterious mutations in genes
responsible for the observed clinical phenotype and muscle
pathology. The diagnoses of 13 families have been con-
firmed by this capture/sequencing approach (R1 in
table 2). Patient 2 had presented with MM due
to PFIS and hyperammonemia since birth. His
muscle pathology was consistent with lipid storage
myopathy (figure 2A). He was homozygous for the
c.199-10T.G Asian common splice mutation in
Figure 1 Coverage depth of 4,815 coding exons of the neuromuscular disease
panel
Table 1 Ten categories of neuromuscular diseases
Name of panel No. Genes
Metabolic myopathies 39 genes ABHD5, ACADM, ACADS, ACADVL, AGL, ALDOA, CPT1A, CPT1B, CPT1C, CPT2, ENO3, ETFA, ETFB,
ETFDH, G6PC, GAA, GBE1, GYG1, GYS1, HADH, HADHA, HADHB, LDHA, LPIN1, PFKM, PGAM2, PGK1,
PGM1, PHKA1, PHKA2, PHKB, PHKG2, PNPLA2, PRKAG2, PYGM, PYGL, SLC22A5, SLC25A20, SLC37A4
Congenital muscular dystrophy 18 genes CHKB, COL6A1, COL6A2, COL6A3, DNM2, FHL1, FKRP, FKTN, GTDC2, ISPD, ITGA7, LAMA2, LARGE,
POMT1, POMT2, POMGNT1, SEPN1, TCAP
Congenital myopathy 21 genes (2) ACTA1, BIN1, CCDC78, CFL2, CNTN1, DNM2, KBTBD13,MTM1,MTMR14,MYBPC3,MYF6,MYH2,MYH7,
NEB, RYR1, SEPN1, TNNT1, TPM2, TRIM3, TTN, TPM3
Other myopathies 16 genes (3) ACVR1, BAG3, CAV3, CRYAB, DES, FHL1, FLNC, GDF8, ISCU, LAMP2, LDB3, PABPN1, PLEC1, SEPN1,
TTID, TTN
Motor neuron disease 37 genes ALS2, ANG, AR, ATP7A, ATXN2, BSCL2, CHMP2B, DCTN1, DYNC1H1, ERBB3, FIG4, FUS, GARS, GLE1,
HSPB1, HSPB3, HSPB8, IGHMBP2, MYBPC1, NEFH, OPTN, PFN1, PIP5K1C, PLEKHG5, PRPH, REEP1,
SETX, SIGMAR1, SMN1, SOD1, TARDBP, TRPV4, UBA1, UBQLN2, VAPB, VCP, VRK1
Congenital myasthenia syndrome 14 genes (1) AGRN, CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, COLQ, DOK7, GFPT1, LAMB2, MUSK, PLEC1, RAPSN,
SCN4A
Arthrogryposis multiplex congenita 21 genes (6) CHRNA1, CHRND, CHRNG, DHCR24, DOK7, ERCC2, ERCC6, FBN2, HRAS, LMNA,MYBPC1,MYH3,MYH8,
RAPSN, RIPK4, TPM2, TNNI2, TNNT3, VIPAR, VPS33B, ZMPSTE24
Myotonic syndromes and ion channel
muscle diseases
20 genes (2) ATP2A1, CACNA1A, CACNA1S, CAV3, CLCN1, DMPK, HSPG2, KCNA1, KCNE1, KCNE2, KCNH2, KCNJ5,
KCNJ11, KCNJ18, KCNQ1, LIFR, SCN4A, SCN4B, SCN5A, ZNF9/CNBP
Charcot-Marie-Tooth diseases and
peroxisomal disorders
58 genes (8) AARS, ARHGEF10, ATL1, CTDP1, DNM2, DNMT1, DYNC1H1, EGR2, FGD4, FIG4, GAN, GARS, GDAP1,
GJB1, HOXD10, HSPB1, HSPB8, IKBKAP, KIF1A, KIF1B, LITAF, LMNA, LRSAM1, MED25, MFN2, MPZ,
MTMR2, NDRG1, NEFL, NGFB, PEX1, PEX2, PEX3, PEX5, PEX6, PEX7, PEX10, PEX11B, PEX12, PEX13,
PEX14, PEX16, PEX19, PEX26, PMP22, PRPS1, PRX, RAB7, SBF2, SEPT9, SH3TC2, SLC12A6, SPTLC1,
SPTLC2, TFG, TRPV4, WNK1, YARS
Other muscular dystrophy 28 genes (14) ANO5, CAPN3, CAV3, DAG1, DES, DMD, DNAJB6, DYSF, EMD, FHL1, FKRP, FKTN, LMNA, MYH7, PLEC1,
POMGNT1, POMT1, POMT2, SGCA, SGCB, SGCD, SGCG, SYNE1, SYNE2, TCAP, TRIM32, TTID, TTN
Total 236 genes 272 genes (36)
A total of 236 genes responsible for the neuromuscular disorders are listed as 10 categories of diseases.
Repeated genes are shown in boldface type, and the number of repeated genes is in parentheses.
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Table 2 Summary of clinical and molecular diagnosis of patients with neuromuscular diseases
Patient
Age at
onset
Current
age, y Sex
Clinical
Dx
Pathologic
Dx Gene symbol Inheritance Mutation Gene name Genetic Dx Final Dx Category
Dx AR (14)
2 NB 1.5 (exp) M MM LSM SLC25A20 Mat c.199-10T.Ga Carnitine acylcarnitine translocase CACTD CACTD R1
SLC25A20 Pat c.199-10T.Ga
3 NB 18.5 M CM CCD RYR1 NA c.11164T.C(p.Y3722H)b Ryanodine receptor 1 CCD, RYR1-related CCD, RYR1-related R1
RYR1 NA c.14584A.G(p.K4862E)b
11 3–4 y 10.9 F CM MMCD SEPN1 Mat c.1096G.T(p.E366*)a,b Selenoprotein N1 MMCD, SEPN1-
related
MMCD, SEPN1-
related
R1
SEPN1 Pat c.1209dup(p.K404Qfs*32)a,b
12 NB 16.2 F CMD DG-CMD POMT1 Mat c.793C.T(p.R265*)a Protein O-mannosyltransferase 1 MDDGB1 CMD, POMT1-
related
R2
POMT1 Pat c.1859G.C(p.R620P)b
16 NB 24.7 M CMD MN-CMD LAMA2 Mat c.2945dup(p.S982Rfs*16)a,b Laminin, a-2 MDC1A MDC1A R1
LAMA2 Pat c.8654T.C(p.L2885P)b
17 10 y 17.8 M MC NSF CLCN1 Mat c.301G.T(p.D101Y)b Chloride channel 1, muscle MCAR MCAR R2
CLCN1 Pat c.1205C.T(p.A402V)a
18 NB 9.1 (exp) F CMT NC IGHMBP2 Pat c.71111G.Ca Immunoglobulin mu-binding protein 2 SMARD1 SMARD1 R3
IGHMBP2 Mat c.2356del(p.A786Pfs*45)a
21 Infancy 17.8 F CM MMCD SEPN1 Mat c.802C.T(p.R268C)a Selenoprotein N1 MMCD, SEPN1-
related
MMCD, SEPN1-
related
R1
SEPN1 Pat c.1574T.G(p.M525R)b
25 NB 22.5 M CM CNM RYR1 NIP c.9658A.G(p.T3220A)b Ryanodine receptor 1 CNM, RYR1-related CNM, RYR1-related R1
RYR1 Pat exon39 het dela,b
26 NB 19.0 M CM CNM RYR1 NIP c.9658A.G(p.T3220A)b Ryanodine receptor 1 CNM, RYR1-related CNM, RYR1-related
RYR1 Pat exon39 het dela,b
32 20 y 31.8 M CM MCNI TCAP Pat c.26_33dup(p.E12Rfs*20)a Titin-cap LGMD2G LGMD2G R3
TCAP Mat c.26_33dup(p.E12Rfs*20)a
33 NB 2.7 F CM ESMC RYR1 Pat c.7795C.T(p.Q2599*)a,b Ryanodine receptor 1 CM, RYR1-related CM, RYR1-related R2
RYR1 Mat c.11737A.G(p.N3913D)b
51 18 y 35.5 F LGMD LGMD2B DYSF NA, cons exon 5 del Dysferlin LGMD2B LGMD2B R1
DYSF exon 5 del
SGCA NA c.662G.A(p.R221H)a Sarcoglycan, a LGMD2D LGMD2D
SGCA NA c.320C.T(p.A107V)
Continued
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Table 2 Continued
Patient
Age at
onset
Current
age, y Sex
Clinical
Dx
Pathologic
Dx Gene symbol Inheritance Mutation Gene name Genetic Dx Final Dx Category
52 13 y 37.4 F LGMD LGMD CAPN3 Sister c.1621C.T(p.R541W)a Calpain 3 LGMD2A LGMD2A R1
CAPN3 Mat/sister c.2305C.T(p.R769W)a
M516 NB 10.0 F CM NM RYR1 Pat c.1675dup(p.I559Nfs*11)a,b Ryanodine receptor 1 NM, RYR1-related NM, RYR1-related R2
RYR1 Mat c.3800C.G(p.P1267R)a
Dx X-R (1)
27 NB 25.5 M CM MTM MTM1 De novo c.679G.A(p.V227M)a Myotubularin MTM, X-linked MTM, X-linked R1
Dx AD (6)
1 NB 6 M CM NSF SPTLC2 (AD) Pat c.1292G.A(p.G431D)b SPT, long-chain base subunit 2 HSAN1C HSAN1C with MHS1 R3
RYR1 (AD) Mat c.7692G.C(p.K2564N)b Ryanodine receptor 1 MHS1
9 NB 0.5 (exp) F CM NM ACTA1 NA c.413T.C(p.I138T)a Muscle actin a1 NEM3 NEM3 R1
19 7 y 34.9 F CMT NC MFN2 S/B c.281G.A(p.R94Q)a Mitofusin 2 CMT2A2 CMT2A2 R1
20 5 y 9.1 M CMT NC MFN2 Mat c.281G.A(p.R94Q)a Mitofusin 2 CMT2A2 CMT2A2
29 15 y 22.1 M MM VM CACNA1S Mat c.4639C.T(p.R1547W)b Calcium channel, voltage-dependent,
L type, a1S
HOKPP1, with
MHS5
HOKPP1, with MHS5 R3
46 NB 2.3 F CM CCD RYR1 De novo c.14581C.T(p.R4861C)a Ryanodine receptor 1 CCD, RYR1-related CCD, RYR1-related R1
M495 3 mo 5.0 M CM NM ACTA1 De novo c.802T.C(p.F268L)a Muscle actin a1 NEM3 NEM3 R1
Likely Dx (8)
7 NB 11.6 M CM MCM SYNE1 (AD/
AR)
Mat c.16388A.C(p.E5463A)b Spectrin repeat-containing nuclear
envelope protein 1
EDMD4 Susp EDMD4 R4
SYNE1 (AD/
AR)
Pat c.1859C.T(p.S620F)
CLCN1 (AD/
AR)
Mat c.1723C.T(p.P575S)a Chloride channel 1, muscle
TTN (AD/AR) Mat c.57388C.T(p.R19130C) Titin
8 Infancy 12.8 F CM MCM RYR1 (AD) Pat c.2203C.T(p.H735Y)b Ryanodine receptor 1 MHS1 Susp CM, RYR1-
related
R4
TTN (AD/AR) Pat c.84995A.G(p.N28332S) Titin
TTN (AD/AR) Mat c.7156 G.A(p.G2386S)b Titin
24 NB 21.8 F CM MTM DMPK (AD) Mat c.625 G.T(p.D209Y)b Dystrophia myotonica protein kinase DM1 Susp DM1 R4
TTN (AD/AR) Mat c.47680A.C(p.K15894Q)b Titin
30 NB 6.3 F CM CNM SYNE1 (AD/
AR)
NIM c.1399A.T(p.K467*)a,b Spectrin repeat-containing nuclear
envelope protein 1
EDMD4 Susp EDMD4 R4
TTN (AD/AR) Mat c.55265A.T(p.D18422V)b
Continued
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Table 2 Continued
Patient
Age at
onset
Current
age, y Sex
Clinical
Dx
Pathologic
Dx Gene symbol Inheritance Mutation Gene name Genetic Dx Final Dx Category
36 3 y 7.8 M CM 2BA TTN (AD/AR) Pat c.5740G.A(p.A1914T) Titin Titinopathy Susp titinopathy R4
TTN (AD/AR) Mat c.71996A.G(p.N23999S)
NEB (AR) Pat c.12742-2A.Ga,b Nebulin NEM2, AR
48 NB 2.8 F CM NM NEB (AR) Pat c.18176A.G(p.N6059S)b Nebulin NEM2, AR Susp NEM2 R4
NEB (AR) Pat c.7062_7063del(p.
K2354Nfs*2)a,b
TTN (AD/AR) Mat c.99298A.C(p.S33100R)b Titin
TTN (AD/AR) Pat c.13811G.A(p.G4604E)
MYH7 (AD) Confirmed c.1322C.T(p.T441M)b Myosin, heavy chain 7, cardiac muscle, b
MYH2 (AD) Confirmed c.4258C.T(p.L1420F) Myosin, heavy chain 2, muscle, adult
54 53 y 55.9 M LGMD ESMC EMD (X-R) Mat c.445G.C(p.D149H) Emerin EDMD1 Susp EDMD1 R4
SYNE1 (AD/
AR)
Pat c.1507T.A(p.S503T)b Spectrin repeat-containing nuclear
envelope protein 1
TTN (AD/AR) Pat c.80173C.T(p.R26725C) Titin
TTN (AD/AR) Pat c.26206G.A(p.A8763T)
56 12 y 27.6 M LGMD MD TTN (AD/AR) Pat c.9216113A.Ta,b Titin Titinopathy Susp titinopathy R4
TTN (AD/AR) Mat c.6490G.A(p.A2164T)
TTN (AD/AR) Mat c.14987G.A(p.R4996Q)b
Abbreviations: 2BA5 type 2 B fiber atrophy; AD5 autosomal dominant; AR5 autosomal recessive; CACTD5 carnitine acylcarnitine translocase deficiency; CCD5 central core disease; CM5 congenital myopathy;
CMD 5 congenital muscular dystrophy; CMT 5 Charcot-Marie-Tooth disease; CMT2A2 5 Charcot-Marie-Tooth disease, axonal, type 2A2; CNM 5 centronuclear myopathy; cons 5 consanguineous; DG 5
dystroglycanopathy; DM1 5 myotonic dystrophy type 1; Dx 5 diagnosis; EDMD 5 Emery-Dreifuss muscular dystrophy; EDMD4 5 Emery-Dreifuss muscular dystrophy 4, autosomal dominant; ESMC 5 end-stage
myopathic change; exp 5 expired; HOKPP1 5 hypokalemic periodic paralysis, type 1; HSAN1C 5 hereditary sensory and autonomic neuropathy, type 1C; LGMD 5 limb-girdle muscular dystrophy; LGMD2B 5
dysferlinopathy; LGMD2G 5 limb-girdle muscular dystrophy type 2G; LGMD2J 5 limb-girdle muscular dystrophy type 2J; LSM 5 lipid storage myopathy; Mat 5 maternal; MC 5 myotonia congenita; MCAD 5
myotonia congenita, autosomal dominant; MCAR 5 myotonia congenital, autosomal recessive; MCM 5minimal change myopathy; MCNI 5 myopathic change with nuclear internalization; MD 5 muscular dystrophy;
MDC1A 5 muscular dystrophy, congenital merosin-deficient 1A; MDDGB1 5 muscular dystrophy-dystroglycanopathy type B1; MHS1 5 malignant hyperthermia susceptibility 1; MHS5 5 malignant hyperthermia
susceptibility 5; MM 5metabolic myopathy; MMCD 5multiminicore disease; MN5merosin negative; MTM 5myotubular myopathy; NA5 not available; NB 5 newborn; NC5 neuropathic change; NEM2 5 nemaline
myopathy 2; NEM3 5 nemaline myopathy 3; NIM 5 not in maternal; NIP5 not in paternal; NM5 nemaline myopathy; NSF5 nonspecific finding; Pat5 paternal; S/B 5 in son and brother; SMARD1 5 spinal muscular
atrophy with respiratory distress 1; Susp 5 suspected (phenotype/genotype now, may need further study); X-R 5 X-linked recessive; VM 5 vacuolar myopathy.
aDefinitive mutation.
bNovel variants.
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SLC25A20,22 which is responsible for carnitine acyl-
carnitine translocase deficiency (CACTD). Each of
his parents was a carrier. Patients 3 and 46 with cen-
tral core disease (CCD) had AR RYR1 mutations and
an AD de novo RYR1mutation, respectively; patients
25 and 26 (siblings) with centronuclear myopathy
(CNM) also had AR RYR1 mutations (figure 2B).
Patients 11 (figure 2C) and 21 with multiminicore
disease had mutations in SEPN1; 2 had nemaline
myopathy (NM) and heterozygous ACTA1 muta-
tions (patients 9 [figure 2D] and M495). Patient 16
with merosin-negative CMD had mutations in
LAMA2; patients 19 and 20, a mother and son with
CMT, had an AD mutation in MFN2; patient 51
with dysferlinopathy and LGMD2B, a consanguine-
ous product, had a homozygous deletion of exon 5 of
DYSF; patient 52 and her affected sister with LGMD
had the same compound heterozygous mutations in
CAPN3; and patient 27 with myotubular myopathy
carried a de novo MTM1 mutation (X-linked).
Ambiguous or nonspecific muscle pathology findings clar-
ified by molecular diagnosis. Sometimes the pathology
findings from a muscle biopsy can be ambiguous
and/or not completely consistent with the known
phenotype caused by a specific disease gene. Mas-
sively parallel sequencing of a group of genes can
resolve the uncertainty. Four families belong to this
category (R2 in table 2). Patient 12 had reduced
a-dystroglycan undiagnosed CMD with end-stage
pathologic muscle changes. Compound heterozygous
mutations in a protein glycosylation gene (POMT1)
were identified and confirmed by parental studies.
Patient 17 had nonspecific muscle findings with a
clinical diagnosis of a myotonic disorder. He was
found to have mutations in a chloride ion channel
gene (CLCN1) and confirmed to have an AR myoto-
nia congenita. Patient 33, a 2.7-year-old girl, pre-
sented with a myopathic face, high-arched palate,
scoliosis, and swallowing and respiratory difficulties
since birth. Her muscle pathology revealed nondiag-
nostic end-stage myopathic changes, although clini-
cally she exhibited typical CM. NGS analysis revealed
compound heterozygous mutations in RYR1, which
confirmed the diagnosis of CM. Patient M516 had
muscle pathology findings suggestive of an atypical
NM and was found to have AR RYR1 mutations:
one frameshift mutation and another missense muta-
tion predicted to be deleterious. Each parent is a car-
rier for one of the mutations. This patient adds to the
short list of NM cases caused by RYR1 mutations.30
Intercategory expansion of phenotype and genotype. Four
families had molecular diagnoses in genes belonging
to a subcategory that was not suspected in the original
clinical evaluation (R3 in table 2). Patient 18 was
Figure 2 Muscle pathology of patients 2, 26, 11, 9, 32, and 48
(A) Markedly increased lipid droplets in both number and size were observed in patient 2 with homozygousSLC25A20mutations (oil red O). (B) Forty percent
myofibers with centralized nuclei were found in patient 26 with compound heterozygous RYR1mutations (hematoxylin and eosin). (C) Multiminicore pattern
was observed in patient 11 with compound heterozygous SEPN1 mutations (nicotinamide adenine dinucleotide tetrazolium reductase). (D) Prominent
nemaline rods were seen in patient 9 with heterozygous ACTA1 mutations (modified Gomori trichrome). (E) Nonspecific myopathic change except for
internalized nuclei and mild fiber size variation was shown in patient 32 with compound heterozygous TCAP mutations (hematoxylin and eosin). (F) Similar
to patient 9, typical intracytoplasmic nemaline rods were present in patient 48 with compound heterozygous NEB mutations (modified Gomori trichrome).
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originally diagnosed as having infantile-onset unclas-
sified CMT. The identification of compound heter-
ozygous mutations in IGHMBP2 confirmed the
diagnosis of spinal muscular atrophy with respiratory
distress type 1 (SMARD1), mainly affecting motor
neurons rather than peripheral nerves. Patient 32, a
32-year-old man, had gait disturbance and mild lower
leg weakness with an elevated creatine kinase since he
was first evaluated at age 20. Muscle biopsy revealed
nuclear internalization without evidence of dystrophic
changes in 10% scattered fibers, favoring a diagnosis
of CNM (figure 2E). The identification of a homozy-
gous frameshift c.26_33dup (p.Glu12Argfs*20)
mutation in TCAP confirmed the diagnosis of LGMD
type 2G. Patient 29, a 22-year-old man, was suspected
of having an MM due to periodic muscle weakness,
abnormal findings in his metabolic profile, and vacu-
olar myopathy in his muscle biopsy. An AD hetero-
zygous novel mutation inherited from his mother was
identified, c.4639C.T (p.Arg1547Trp) in CAC-
NA1S, encoding a calcium channel protein, consistent
with hypokalemic periodic paralysis. AD CACNA1S
mutations have been found in Asian men with peri-
odic muscle weakness and risk for malignant hyper-
thermia (MH), but they exhibit lower penetrance in
women.31 Patient 1 showed a positive Gowers sign
and waddling gait when first evaluated at 4 years of
age; however, the EMG, nerve conduction velocity,
and muscle pathology were unremarkable at that time.
The finding of the AD SPTLC2mutation c.1292G.A
(p.Gly431Asp), confirmed clinically and genetically in
his biological father, established the unexpected diag-
nosis of a neuropathy (hereditary sensory and auto-
nomic neuropathy [HSAN] type 1C).
Interesting cases with likely diagnosis and expansion of
phenotype/genotype. Eight families had novel pheno-
type/genotype diagnoses that require further func-
tional evidence of pathogenicity (R4 in table 2).
Patient 56 had a clinical and pathologic diagnosis of
LGMD. NGS revealed 3 TTN variants: the
c.9216113A.T from the father was predicted to
abolish the normal splice site, while a novel
c.14987G.A (p.Arg4996Gln) variant in cis with
another variant, c.6490G.A (p.Ala2164Thr), were
both inherited from the mother. These 2 missense
variants were predicted to be deleterious by
PolyPhen-2 and SIFT. Mutations in TTN can cause
AR LGMD type 2J. The growing genetic complexity
and emerging phenotypic variability for recessive and
dominant TTN variants make the assignment of
definitive pathogenicity to many TTN variants diffi-
cult and delay our understanding of the pathogenic
mechanism of the largest protein known to date.32 In
addition to compound heterozygous TTN variants of
unknown significance (VUS), patients 36 and 48
each had a heterozygous truncating mutation (a splice
site novel mutation c.12742-2A.G and a frameshift
mutation c.7062_7063del, respectively) in the NEB
gene (table 2).33 Each patient inherited the deleteri-
ousNEB allele from the father. Despite the absence of
the second mutant allele, muscle biopsy of patient 36
revealed only a nonspecific type 2B fiber atrophy,
while patient 48 did show an NM (figure 2F). Patient
54 was suspected of having Emery-Dreifuss muscular
dystrophy (EDMD) due to the X-linked EMD gene,
of which his mother was a carrier. His cardiac phe-
notype of complete right bundle branch block may be
due to an emerin mutation, but his clinical and path-
ologic features are not typical of EDMD. The positive
emerin staining in the muscle biopsy did not rule out
a pathogenic role of this emerin variant.34
Defective genes and diagnostic yields. In our patient
cohort, CM was the most common diagnosis (23/38,
61%), followed by CMD and LGMD. Since parallel
analysis of all 236 NMD-related genes in a clinically
validated panel is a recent innovative approach
to testing, the majority of mutations/variants are
“novel.” Theoretically, all missense variants should
be classified as VUS until a functional defect can be
demonstrated. However, if a VUS is found in patients
with a consistent clinical phenotype, family pedigree,
and muscle biopsy findings and is predicted to be
deleterious, then it is classified as likely pathogenic.
AR disorders account for about half of the cases,
while AD cases account for about a quarter. Overall,
our NMD gene panel analysis provides a diagnostic
yield of 29/35 (83%), which is the highest reported
in complex NMD cases in the NGS era.
DISCUSSION To date, except when using whole-
exome sequencing and whole-genome sequencing for
novel gene discovery, most NGS studies have focused
on a specific NMD category, such as CMD,17
CMyS,18 CMT,19 dystrophinopathy,20 glycogen
storage disease,21 or CACTD.22 In this report, we
analyzed 236 genes responsible for 10 NMD
subcategories. Surprisingly, some patients were found
to harbor mutations in genes responsible for disease
categories that were not initially considered
(IGHMBP2, TCAP, SPTLC2, CACNA1S). This
observation confirms that clinical features, muscle
imaging, and muscle pathology may be suggestive of a
specific diagnosis but that the ultimate diagnosis relies
on the identification of mutations in the causative
gene(s). Furthermore, some patients are evaluated at a
very early or late stage of their disease, when the details
of their early clinical course may not be available and the
muscle pathology may provide limited information.
Under these circumstances, it is very difficult to focus
on a specific disease category for the analysis of a single
gene or a few genes. Thus, comprehensive NGS analysis
of all NMD-related genes provides a cost-effective way
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to identify causative mutations. Evidence for this is
provided by patient 1. The mutation analysis not only
established the unexpected diagnosis of HSAN type 1C
but also underscored the importance of molecular
diagnosis through NGS.35 Similarly, patient 18 was
originally diagnosed as having congenital neuropathy,
CMT type. The identification of mutations in
IGHMBP2 changed the final diagnosis to SMARD1
and further expanded the intercategory phenotype/
genotype.36 The identification of IGHMBP2
mutations facilitated the subsequent prenatal diagnosis
that resulted in a normal fetus.
Our comprehensive NGS approach achieves a
diagnostic yield of 83% for the highly genetically
and clinically complex NMDs. Our capture/NGS
approach has at least 2 unique advantages: (1) a com-
prehensive evaluation of 236 target genes to minimize
variations in the coverage depth of individual exons,
and (2) deep coverage depth at a mean of .1,0003
per base, leaving only ;0.6% of coding exons con-
taining insufficiently covered (,203) sequences
requiring PCR/Sanger to complete. Thus, consistent
coverage of individual exons allows the detection of
deletions in .99% of targeted exons.29 This is dem-
onstrated by the identification of a single exon dele-
tion in patient 51 (figure not shown) and by patients
25 and 26 (siblings), in whom both NGS and Sanger
sequence analyses identified a heterozygous point
mutation (p.Thr3220Ala) in RYR1 (figure 3A), while
copy number analysis using the same set of NGS data
detected a heterozygous single exon deletion (figure
3B). The deletion was confirmed by using PCR across
the deleted exon (figure 3C), showing the reduced size
of PCR product (figure 3D).
Sequence variations in RYR1 and TTN are fre-
quent. This may be related to their relatively large size.
Patients with mutations in these 2 genes may exhibit
diverse clinical phenotypes and variable muscle pathol-
ogy. For example, in our patient cohort, both AR and
AD RYR1 mutations were identified in muscle biop-
sies of patients with CCD (patient 3 AR and patient
46 AD), CNM (patient 26), CM with end-stage myo-
pathic change (patient 33), atypical NM (patient
M516), and nonspecific findings (patient 1). Patients
with RYR1mutations may also be predisposed toMH.
Thus, attention should be paid in anesthetic arrange-
ments to avoid iatrogenic morbidity.37,38 Although
NM is one of the most common types of CM,12 we
found only 2 patients with AD inheritance (9 and
M495), both of whom had ACTA1 mutations.
The TTN gene has not been extensively studied,
likely in part due to its size. Sequencing of this
Figure 3 Confirmation of single exon deletion and point mutation in RYR1 detected by next-generation sequencing
(A) Sanger sequence for heterozygous c.9658A.G (p.T3220A). (B) Exon 39 heterozygous deletion was detected by copy number variation analysis. (C)
Designed primers for exon 39 deletion. Forward primer: F, reverse primer: R, the total length between the primers is 4.3 kb. (D) DNA gel for exon 39 deletion;
patients 25 and 26 have extra small fragments on the gel (;2.7 kb).
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gigantic gene (complementary DNA ;0.1 Mb) only
became practical with NGS technology. Therefore,
we have just begun to identify and understand its
genetic diseases and mechanisms of inheritance.
TTN mutations have been identified in patients with
heterogeneous clinical phenotypes, including CM,
LGMD, and others, with highly variable muscle
biopsy findings.1,8,11,39,40 In this study, we have dem-
onstrated the power of target gene capture followed
by NGS. This comprehensive approach confirms
clinical and pathologic diagnoses when the phenotype
is consistent with the causative gene. It also clarifies a
patient’s underlying genetic cause when a muscle
biopsy finding is ambiguous or does not comport
with the clinical phenotype. Since the number of
genes analyzed is large, it often identifies mutations
in genes that may not have been considered in the
clinical differential diagnosis, therefore expanding the
phenotype/genotype relationship. Although ulti-
mately this comprehensive noninvasive approach is
much less expensive and more definitive for molecu-
lar diagnosis of the heterogeneous and complex
NMDs, muscle pathology and thorough clinical eval-
uation are still important in the final clinical pheno-
type/genotype correlation, particularly at the early
stage of expanding phenotype/genotype.
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